NH Business Review
‘First pandemic roadmap driven by the manufacturing sector’
April 22, 2021
What it calls a roadmap to strengthen and accelerate pandemic response and preparedness in the U.S. has been launched by the Manchester-based Advanced Regenerative Manufacturing Institute.
The initiative – called the National Technology Roadmap for Pandemic Response and Recovery – outlines a technology-based action plan for dealing with pandemics. It recommends special technology and commercialization efforts that could be implemented to respond to and recover from Covid-19,as well as longer-term research and development priorities necessary to improve readiness.
In its announcement, ARMI said the strategy is “the first pandemic roadmap driven by the manufacturing sector. Given that the manufacturing sector will be at the center of a stronger, faster and more coordinated U.S. response to and recovery from Covid-19 and future pandemics, this roadmap will help ensure U.S. prepar
(Bloomberg) Talk about nosedives.
Hopes for the flying car soared in January, when one manufacturer, Woburn, Massachusetts-based Terrafugia, attained a long-awaited industry first: a Federal Aviation Authority airworthiness certificate for its Transition, a “roadable aircraft” a winged, gas-powered, wheeled vehicle that can be both driven and flown. Suddenly the aerial sedan, first popularized in the 1960s cartoon The Jetsons, needed only U.S. Department of Transportation approval before it could be let loose on America’s highways and flyways. Terrafugia hailed a “major accomplishment.” Champagne corks flew.
We apologize, but this video has failed to load.
Try refreshing your browser, or
De-risking the Manufacturing of Cell Therapies through Virus-Inactivated Products, Upcoming Webinar Hosted by Xtalks
Share Article
In this free webinar, the featured speakers will discuss the challenges posed by human blood-derived ancillary materials and the strategies employed by suppliers to mitigate these risks. Attendees will also learn about a layered approach to providing safe and effective therapeutic biologics.
As advanced therapies progress through the clinical pipeline, the integrity of the materials used during manufacture becomes increasingly critical. TORONTO (PRWEB) February 24, 2021 As advanced therapy developers approach approval and commercialization, they adopt increasingly robust risk-based approaches to ancillary material qualification. Ancillary material qualification is defined by USP 1043 as “the process of acquiring and evaluating data to establish the source, identity, purity, biologi
CollPlant Issues Letter to Shareholders
USA - English
Expansion of collaboration with United Therapeutics to cover a second lifesaving organ, human kidneys, in addition to lungs
Development and commercialization agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen to be used in dermal and soft tissue filler products
Growing revenues and strong cash position, allowing execution of our strategic plan
News provided by
Share this article
Share this article
REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders.
Dear shareholders,
Dermal filler treatment
BioInk development
Share this article
Share this article
ResearchAndMarkets.com s offering.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term.
An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic syst